Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Brompheniramine maleate

Brompheniramine maleate: 2 brands, 16 generics; first approved Jan 25, 1983; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 16 ANDA applications approved.

Brands (NDA)
2
Generics (ANDA)
16
Listed patents
0
Presentations
20

Brand (NDA) products

Originator applications
  • NDA 01079919833 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
    8MGTABLET, EXTENDED RELEASEORALDiscontinued
    12MGTABLET, EXTENDED RELEASEORALDiscontinued
  • NDA 011418
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MG/MLINJECTABLEINJECTIONDiscontinued

Generic (ANDA) products (16)

Abbreviated applications
  • BROMPHENIRAMINE MALEATE
    ANDA 0886041984
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 0879641983
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2MG/5MLELIXIRORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 086936
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2MG/5MLELIXIRORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 085466
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2MG/5MLELIXIRORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 087517
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2MG/5MLELIXIRORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 083821
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MG/MLINJECTABLEINJECTIONDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 083820
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    100MG/MLINJECTABLEINJECTIONDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 084468
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 084351
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 086987
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 086187
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 087009
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 083215
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 085850
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 083123
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued
  • BROMPHENIRAMINE MALEATE
    ANDA 085769
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    4MGTABLETORALDiscontinued

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
44 yr 2 mo ago
Most recent approval
42 yr 8 mo ago

Approvals span 1983–1984 across 18 FDA applications.

Brand (NDA) 211%
Generic (ANDA) 1689%

Brompheniramine maleate: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.